Gregory M. Glenn - 15 Nov 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President, R&D
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
15 Nov 2021
Net transactions value
-$1,399,434
Form type
4
Filing time
17 Nov 2021, 16:25:59 UTC
Previous filing
12 Nov 2021
Next filing
24 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $14,380 +521 +13% $27.60 4,582 15 Nov 2021 Direct F1
transaction NVAX Common Stock Options Exercise $30,452 +662 +14% $46.00* 5,244 15 Nov 2021 Direct F1
transaction NVAX Common Stock Sale $203,496 -1,183 -23% $172.02* 4,061 15 Nov 2021 Direct F1, F2
transaction NVAX Common Stock Options Exercise $157,410 +8,250 +203% $19.08 12,311 16 Nov 2021 Direct F1
transaction NVAX Common Stock Sale $83,446 -500 -4.1% $166.89* 11,811 16 Nov 2021 Direct F1, F3
transaction NVAX Common Stock Sale $247,225 -1,472 -12% $167.95* 10,339 16 Nov 2021 Direct F1, F4
transaction NVAX Common Stock Sale $223,969 -1,326 -13% $168.91* 9,013 16 Nov 2021 Direct F1, F5
transaction NVAX Common Stock Sale $740,977 -4,352 -48% $170.26* 4,661 16 Nov 2021 Direct F1, F6
transaction NVAX Common Stock Sale $102,562 -600 -13% $170.94* 4,061 16 Nov 2021 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 -521 -34% $0.000000 1,024 15 Nov 2021 Common Stock 521 $27.60 Direct F1, F8
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 -662 -7.1% $0.000000 8,606 15 Nov 2021 Common Stock 662 $46.00 Direct F1, F9
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 -8,250 -7.1% $0.000000 107,250 16 Nov 2021 Common Stock 8,250 $19.08 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.01 to $172.07, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.33 to $167.22, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.49 to $168.42, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.61 to $169.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F6 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.62 to $170.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F7 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.69 to $171.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F8 Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
F9 Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
F10 On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date.